Mutant of L1 protein of human papillomavirus type 16

US11213580B2 · kind B2 · utility

Assignees

• XIAMEN UNIVERSITY · CN
• Xiamen Innovax Biotech Co., Ltd. · CN

Inventors

• Ying Gu · Fujian, CN
• Shaowei Li · Potomac, US
• Shuo Song · Xiamen, CN
• Maozhou He · Xiamen, CN
• Zhihai Li · Xiamen, CN
• Ningshao Xia · Fujian, CN

Key dates

• Filing date: Jul 13, 2018
• Grant date: Jan 4, 2022
• Expiry date: Aug 10, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2710/20034
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are a mutated HPV16 L1 protein (or a variant thereof), a sequence encoding the same and a method for preparing the same, as well as a virus-like particle comprising the same. The protein (or variant thereof) and the virus-like particle are capable of inducing neutralizing antibodies against at least two types of HPV (e.g., HPV16 and HPV35, or HPV16, HPV35, and HPV31), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. Also provided are a use of the above protein and virus-like particle in the manufacture of a pharmaceutical composition or vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.